| Autor: |
WANG Qiuqin, ZHANG Yutong, XU Yuchen, BAI Yamei, CHEN Hua, JIANG Rongrong, YAN Shuxia, WANG Qing, XU Guihua, XIE Ying, QIAO Chun, YANG Juan |
| Jazyk: |
čínština |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Zhongguo quanke yixue, Vol 26, Iss 17, Pp 2155-2161 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1007-9572 |
| DOI: |
10.12114/j.issn.1007-9572.2022.0904 |
| Popis: |
Background Parkinson's disease (PD) , as one of the most common neurodegenerative diseases, has become a global medical problem due to the obvious adverse reaction of drug treatment and the reduced efficacy of long-term use. Guasha is one of the widely used non-drug therapies of traditional Chinese medicine (TCM) with unique advantages in the treatment of nervous system diseases. At present, there are few studies on the treatment of idiopathic PD with Guasha combined with drug therapy. Objective To explore the short-term clinical effect of Guasha combined with drug therapy for idiopathic PD. Methods Sixteen patients with idiopathic PD in the early and middle stages selected by the purposive sampling method from March 2021 to September 2021 in outpatients of Nanjing Hospital of Chinese Medicine and Jiangsu Province Hospital were selected as the observation group, and another 16 patients with idiopathic PD were selected as the control group according to the principle of matching gender, age, course of disease and Hoehn-Yahr stage. The observation group was treated with Guasha combined with western medicine orally for 4 weeks as a course of treatment; after 3 courses of treatment, Guasha was stopped and western medicine orally continued for 1 course of treatment as follow-up. The control group was treated with simple western medicine orally for 4 weeks as a course of treatment, and the last one of 4 courses of treatment was recorded as follow-up. After 3 months of treatment and 1 month of follow-up, the Movement Disorder Society-Unified Parkinson's Disease Rating ScaleⅢ (MDS-UPDRSⅢ) score, Non-motor Symptom Score (NMSS) and clinical efficacy were observed. The levels of serum interleukin-1β (IL-1β) and nuclear transcription factor κB (NF-κB) were observed after 3 months of treatment. Results After 3 months of treatment, the scores of MDS-UPDRS Ⅲ and NMSS, and the levels of serum IL-1β and NF-κB in two groups were lower than those before treatment (P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
